{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-018964","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.714287+00:00","generated_at":"2026-06-01T06:44:24.647284+00:00","sec_items":["1.01","2.03","7.01","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Omeros enters $92.1M term loan, repurchases $118.1M convertible notes at 74.75% of par, extinguishes $51M debt","bullets":["New $67.1M initial term loan funded June 3, 2024, plus $25M delayed draw available upon FDA approval of narsoplimab for TA-TMA.","Used $67.1M loan and $21.2M cash to repurchase $118.1M (55%) of 5.25% convertible notes due 2026, resulting in $51M debt extinguishment.","Non-dilutive transaction; no equity component. Loans mature June 3, 2028, with interest at SOFR (3% floor) + 8.75% per annum.","Credit agreement requires maintaining ≥$25M unrestricted cash; additional repurchases of 2026 notes permitted under limitations.","After repurchase, $97.9M of 2026 notes outstanding; Omeros retains flexibility to exchange up to $16.9M notes for cash and additional term loans."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-018964","json":"https://secwatch.observer/filing/0001437749-24-018964.json","markdown":"https://secwatch.observer/filing/0001437749-24-018964.md","text":"https://secwatch.observer/filing/0001437749-24-018964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924018964/0001437749-24-018964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924018964/omer20240531_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:44:24.647284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}